Tasuku Honjo

Tasuku Honjo is a Nobel Laureate (2018) who discovered PD-1 and its critical role in regulating T cell responses. His work revealed that PD-1/PD-L1 interaction serves as an immune checkpoint that tumors exploit to evade immunity. This discovery led to the development of anti-PD-1/PD-L1 antibodies (pembrolizumab, nivolumab, atezolizumab) that have become standard-of-care for many cancer types.

本庶佑是2018年诺贝尔奖获得者，发现了PD-1及其在调节T细胞反应中的关键作用。他的工作揭示了PD-1/PD-L1相互作用作为肿瘤利用以逃避免疫的免疫检查点。这一发现导致了抗PD-1/PD-L1抗体（pembrolizumab、nivolumab、atezolizumab）的开发，这些抗体已成为许多癌症类型的标准治疗。